Results 111 to 120 of about 33,889 (223)

Deregulation of the cyclin-dependent kinase inhibitor p27 as a putative candidate for transformation in Chlamydia trachomatis infected mesenchymal stem cells. [PDF]

AIMS Microbiol, 2023
Abu-Lubad MA, Al-Zereini W, Al-Zeer MA.
europepmc   +1 more source

Expression and significance of cyclin D1, cyclin-dependent kinase 4 and cyclin-dependent kinase inhibitor P27 in patients with non-neoplastic epithelial disorders of the vulva. [PDF]

Exp Ther Med, 2023
Liu H, Zhang F, Li Z.
europepmc   +1 more source

Suppression of cell cycle progression by Jun dimerization protein (JDP2) involves down-regulation of cyclin A2 [PDF]

, 2009
We report here a novel role for Jun dimerization protein-2 (JDP2) as a regulator of the progression of normal cells through the cell cycle. To determine the role of JDP2 in vivo, we generated Jdp2 knock-out (Jdp2KO) mice by targeting exon 1 to disrupt ...
Atsushi Yoshiki, Hitomi Hasegawa, Jianzhi Pan, Kazunari K. Yokoyama, Koji Nakade, Naoto Yamaguchi, Satoko Masuzaki, Takehide Murata, Yu-Chang Huang, Yuichi Obata   +9 more
core   +1 more source

eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]

, 2019
CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina, Foulkes, William D., Fu, Zheng, Guiot, Marie-Christine, Huang, Sidong, Kong, Tim, Monast, Anie, Park, Morag, Pelletier, Jerry, Pilon, Virginie, Porco, John A., Sangwan, Veena, Xue, Yibo, Zhu, Xianbing   +13 more
core   +1 more source

Understanding signaling cascades in melanoma [PDF]

, 2008
Understanding regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now appreciated that melanoma is the result of complex changes in multiple signaling pathways that affect growth control,
Akslen L. A., Berger A. J., Berking C., Bhoumik A., Bhoumik A., Chen X., Claffey K. P., Collisson E. A., Coppock D. L., Dahia P. L. M., Dhawan P., Dorsky R. I., Ehebauer M., Eisenmann K. M., Genersch E., Goding C. R., Goodall J., Gorden A., Guldberg P., Gurzov E. N., Herbst R. A., Hingorani S. R., Hughes M. J., Huguier S., Iozzo R. V., Jonsson M., Jorgensen K., Karin M., Kennedy N. J., Kumar R., Lacal P. M., Li N., Maeno K., Meyskens F. L., Miller J. R., Miyazono K., Niu G., Okuyama R., Omholt K., Park B. K., Piek E., Qin J.-Z., Rangaswami H., Rimm D. L., Rofstad E. K., Satyamoorthy K., Soldatencov V. A., Stewart F. A., Tago K.-i., Thomson J. A., Tokita T., Tsai E. Y., Tsao H., van Elsas A., Wu M., Yang J., Yang J., Yang Y. M., Zhou X. P.   +58 more
core   +1 more source

Berberine Inhibits Growth and Induces G1 Arrest and Apoptosis in Human Cholangiocarcinoma QBC939 Cells

Journal of Pharmacological Sciences, 2012
The chemotherapeutic approach using non-toxic natural products may be one of the strategies for the management of the cholangiocarcinoma. Here we report that in vitro treatment of human cholangiocarcinoma QBC939 cells with berberine, a naturally ...
Wei He, Bin Wang, Yun Zhuang, Dong Shao, Kewen Sun, Jianping Chen   +5 more
doaj   +1 more source

Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers

Gastroenterology Research and Practice, 2016
Background. Gastric cancer is known for a notable variety in the course of the disease. Clinical factors, such as tumor stage, grade, and localization, are key in patient survival.
Petra Minarikova, Lucie Benesova, Tereza Halkova, Barbora Belsanova, Inna Tuckova, Frantisek Belina, Ladislav Dusek, Miroslav Zavoral, Marek Minarik   +8 more
doaj   +1 more source

Distinct outcomes from targeted perturbations of the multi-subunit SCFSkp2 E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis

Communications Biology
Identifying effective therapies targeting multi-protein complexes that lack catalytic sites or cofactor pockets remains a long-standing challenge. The proto-oncogene, ubiquitin E3 ligase SCFSkp2, is one such target.
Yingjiao Xue, Liang Zhu, Saumen Karan, Joseph D. Locker, Craig Branch, Jinghang Zhang, Bang Hoang, Juan Pablo Maianti, Hongling Zhao, Edward L. Schwartz   +9 more
doaj   +1 more source

PPAR-alpha: a novel target in pancreatic cancer [PDF]

, 2015
Background: Current targeted therapies in pancreatic cancer have been ineffective. The tumor stroma, including intra- and peri-tumoral inflammation and fibrosis, is increasingly implicated in pancreatic cancer.
Hua, Alexander Mach
core   +1 more source

Cyclin-dependent kinase inhibitor 1B (p27; Kip1; CDKN1B; p27Kip1) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source